IRD
Opus Genetics, Inc. NASDAQ$5.22
Mkt Cap $372.7M
52w Low $0.90
88.0% of range
52w High $5.81
50d MA $4.78
200d MA $2.62
P/E (TTM)
-6.4x
EV/EBITDA
-31.2x
P/B
208.1x
Debt/Equity
0.0x
ROE
-323.1%
P/FCF
-35.5x
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
$4.78
200d MA
$2.62
Avg Volume
966.6K
About
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.11 | -0.14 | -27.3% | 4.85 | +3.1% | +3.3% | -0.2% | +3.7% | +7.0% | -1.0% | +13.4% | — |
| Nov 12, 2025 | AMC | -0.14 | -0.12 | +14.3% | 1.92 | +2.1% | -3.6% | -2.1% | -9.4% | -2.1% | -3.1% | +22.9% | — |
| Aug 13, 2025 | AMC | -0.25 | -0.12 | +52.0% | 1.10 | -4.5% | +7.3% | +9.1% | +4.5% | +0.9% | +5.5% | +25.5% | — |
| May 15, 2025 | AMC | -0.34 | -0.32 | +5.9% | 0.95 | -1.1% | +7.4% | +6.3% | +4.6% | +7.4% | +6.3% | -0.9% | — |
| Mar 31, 2025 | AMC | -0.34 | -1.27 | -273.5% | 0.98 | +0.4% | -7.3% | -5.0% | -0.2% | -9.7% | -13.8% | -3.2% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.29 | +3.3% | 1.14 | +0.9% | -5.3% | -7.0% | -7.0% | -20.1% | -22.5% | -2.6% | — |
| Aug 13, 2024 | AMC | -0.25 | -0.30 | -20.0% | — | — | — | — | — | — | — | — | — |
| May 10, 2024 | AMC | -0.18 | -0.29 | -61.1% | — | — | — | — | — | — | — | — | — |
| Mar 9, 2024 | AMC | -0.05 | -0.22 | -315.2% | — | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -0.22 | 0.25 | +211.8% | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Citizens | Initiates | Mkt Perform | $12 | $5.12 | $5.09 | -0.6% | -2.3% | -8.8% | -0.2% | +0.4% | — |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $5.01 | $5.05 | +0.8% | -3.4% | +0.4% | +3.6% | -4.2% | -7.0% |
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $5.01 | $5.05 | +0.8% | -3.4% | +0.4% | +3.6% | -4.2% | -7.0% |
| Mar 2 | BTIG | Maintains | Buy → Buy | — | $4.16 | $4.08 | -1.9% | +4.1% | +2.2% | +9.9% | +14.7% | +17.5% |
| Jan 28 | BTIG | Maintains | Buy → Buy | — | $2.83 | $2.84 | +0.4% | -4.6% | -11.7% | -18.4% | -18.0% | -15.2% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $1.92 | $1.96 | +2.1% | -3.6% | -2.1% | -9.4% | -2.1% | -3.1% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $2.03 | $2.04 | +0.5% | -1.5% | -3.0% | -3.0% | -5.4% | -8.9% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.02 | $1.02 | +0.0% | -4.3% | -7.6% | -7.9% | -2.9% | -2.0% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.98 | $0.99 | +0.4% | -7.3% | -5.0% | -0.2% | -9.7% | -13.8% |
| Apr 1 | Jones Trading | Maintains | Buy → Buy | — | $0.98 | $0.99 | +0.4% | -7.3% | -5.0% | -0.2% | -9.7% | -13.8% |
Recent Filings
8-K · 2.03
! Medium
Opus Genetics, Inc. -- 8-K 2.03: Credit Facility
Opus Genetics (IRD) secured senior secured notes financing from OPCM SA LLC and other purchasers, creating a new debt obligation to fund operations and growth initiatives.
Apr 24
8-K
Opus Genetics, Inc. -- 8-K Filing
I appreciate the request, but I cannot write a meaningful sentence based on this summary. The provided text only describes filing mechanics rather than substantive business news, material events, or deal outcomes that would impact investors.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
George Magrath's appointment as CEO at Ishares Trust (IRD) signals potential strategic direction shifts; investors should monitor whether new leadership drives operational improvements or signals underlying governance concerns.
Apr 7
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
IRD secured new financing from OPCM SA LLC, which likely provides capital for operations or growth but investors should monitor debt terms and repayment obligations that could dilute shareholders or constrain future flexibility.
Apr 7
8-K
Unknown — 8-K Filing
Opus Genetics advancing its clinical-stage gene therapy pipeline with consistent milestone progress, though pre-revenue status means stock value depends entirely on upcoming trial data success and funding runway.
Mar 10
8-K · 8.01
!! High
Opus Genetics, Inc. -- 8-K 8.01: Material Event / Announcement
Opus Genetics announced a material event that could significantly impact investor returns, but specific details require reviewing the full filing to assess whether this represents positive news, regulatory action, or strategic changes affecting stock valuation.
Feb 19
Data updated apr 25, 2026 4:12pm
· Source: massive.com